Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 7/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471245 | 0.89 | GRIA4 (0.50) | GRIA4GRIA2GRM2 | |
| SCHEMBL4373917 | 0.86 | GRIA4 (0.55) | GRIA4GRIA2PPARGLMNAL3MBTL1 | |
| SCHEMBL4369462 | 0.86 | GRIA4 (0.44) | GRIA4GRIA2PPARGLMNAL3MBTL1 | |
| SCHEMBL4373295 | 0.86 | GRIA2 (0.59) | GRIA4GRIA2LMNAL3MBTL1 | |
| SCHEMBL4563025 | 0.85 | GRM2 (0.40) | GRIA4GRIA2PPARGLMNAL3MBTL1 | |
| SCHEMBL4369475 | 0.85 | FNTA (0.47) | GRIA4GRIA2LMNAALDH1A1 | |
| SCHEMBL4370215 | 0.84 | GRIA4 (0.44) | GRIA4GRIA2ALDH1A1HTTNPSR1 | |
| SCHEMBL4373299 | 0.82 | GRIA4 (0.56) | GRIA4GRIA2LMNAALDH1A1HTT | |
| SCHEMBL4373078 | 0.80 | GRIA4 (0.58) | GRIA4GRIA2L3MBTL1ALDH1A1HTT | |
| SCHEMBL8289785 | 0.79 | GRIA2 (0.60) | GRIA4GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | GRIA4 16/4885GRIA2 17/4885PPARG 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.